MRUS

MRUS - Merus NV Stock Price, Fair Value and News

$90.00 
Market Closed as of 02 Jan 2026, 04:00 pm ET

MRUS Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

MRUS Price Action

MRUS RSI Chart

MRUS Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

MRUS Valuation

MRUS Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

MRUS Fundamentals

MRUS Revenue

MRUS Earnings

MRUS Profitability

MRUS Investor Care

Revenue & Growth

How Merus NV generates revenue and covers its expenses, based on the latest reported earnings.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
202554.7M56.2M56.6M-
202438.3M35.2M35.9M36.1M
202343.4M41.2M45.7M43.9M
202252.4M52.7M45.6M41.6M
202132.0M38.3M43.4M49.1M
202028.6M28.3M28.7M29.9M
201936.6M34.8M32.9M31.1M
201826.0M30.1M34.3M38.4M
20177.4M12.2M17.1M21.9M
2016---2.5M
2015---1.9M
MRUS
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; and collaboration with Incyte Corporation for the development of MCLA-145. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.
 CEO
 WEBSITEmerus.nl
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES164